within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK01_Dapagliflozin;

model Dapagliflozin
  extends Pharmacolibrary.Drugs.ATC.A.A10BK01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BK01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes mellitus. It lowers blood glucose by promoting urinary glucose excretion and has also been approved to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers (both male and female) after single oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Kasichayanula, S, et al., &amp; Boulton, DW (2014). Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. <i>Clinical pharmacokinetics</i> 53(1) 17–27. DOI:<a href=\"https://doi.org/10.1007/s40262-013-0104-3\">10.1007/s40262-013-0104-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24105299/\">https://pubmed.ncbi.nlm.nih.gov/24105299</a></p></li><li><p>Dhillon, S (2019). Dapagliflozin: A Review in Type 2 Diabetes. <i>Drugs</i> 79(10) 1135–1146. DOI:<a href=\"https://doi.org/10.1007/s40265-019-01148-3\">10.1007/s40265-019-01148-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31236801/\">https://pubmed.ncbi.nlm.nih.gov/31236801</a></p></li><li><p>Tirucherai, GS, et al., &amp; Boulton, DW (2016). Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus. <i>Diabetes, obesity &amp; metabolism</i> 18(7) 678–684. DOI:<a href=\"https://doi.org/10.1111/dom.12638\">10.1111/dom.12638</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27291448/\">https://pubmed.ncbi.nlm.nih.gov/27291448</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Dapagliflozin;
